1. Home
  2. SSTK vs PRME Comparison

SSTK vs PRME Comparison

Compare SSTK & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shutterstock Inc.

SSTK

Shutterstock Inc.

N/A

Current Price

$2.20

Market Cap

570.9M

Sector

Technology

ML Signal

N/A

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

N/A

Current Price

$3.57

Market Cap

526.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SSTK
PRME
Founded
2003
2019
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
570.9M
526.0M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
SSTK
PRME
Price
$2.20
$3.57
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
★ $7.39
AVG Volume (30 Days)
901.5K
★ 5.6M
Earning Date
11-05-2026
11-12-2026
Dividend Yield
★ 44.49%
N/A
EPS Growth
★ 23.76
18.18
EPS
N/A
★ N/A
Revenue
N/A
★ $4,632,000.00
Revenue This Year
N/A
$150.97
Revenue Next Year
N/A
$18.06
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 55.28
52 Week Low
$2.20
$2.67
52 Week High
$21.68
$5.91

Technical Indicators

Market Signals
Indicator
SSTK
PRME
Relative Strength Index (RSI) 24.82 43.80
Support Level N/A $2.89
Resistance Level $4.67 $3.74
Average True Range (ATR) 0.33 0.45
MACD -0.08 -0.12
Stochastic Oscillator 1.24 5.02

Price Performance

Historical Comparison
SSTK
PRME

About SSTK Shutterstock Inc.

Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: